William Blair Has Bearish Estimate for TLX FY2025 Earnings

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) – Investment analysts at William Blair cut their FY2025 earnings per share estimates for Telix Pharmaceuticals Limited American Depositary Shares in a research note issued on Wednesday, March 12th. William Blair analyst A. Hsieh now expects that the company will earn $0.82 per share for the year, down from their prior estimate of $0.83. William Blair has a “Outperform” rating on the stock. The consensus estimate for Telix Pharmaceuticals Limited American Depositary Shares’ current full-year earnings is $0.24 per share. William Blair also issued estimates for Telix Pharmaceuticals Limited American Depositary Shares’ FY2026 earnings at $1.05 EPS.

Separately, UBS Group raised their price target on Telix Pharmaceuticals Limited American Depositary Shares from $21.00 to $22.00 and gave the company a “buy” rating in a report on Monday, January 27th.

Telix Pharmaceuticals Limited American Depositary Shares Stock Up 1.8 %

Shares of NASDAQ:TLX opened at $17.30 on Friday. Telix Pharmaceuticals Limited American Depositary Shares has a 1-year low of $14.01 and a 1-year high of $30.36. The firm’s fifty day moving average is $17.47.

About Telix Pharmaceuticals Limited American Depositary Shares

Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.